SCHEMBL5768620

SCHEMBL5768620

COc1c(B(O)O)ccc2c1CCCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
BCL2L1 Q07817 1/20 0.36
BAD Q92934 1/20 0.36
TUBB4A P04350 2/20 0.34
TUBB P07437 2/20 0.34
TUBA3C P0DPH7 2/20 0.34
TUBA1B P68363 2/20 0.34
TUBA4A P68366 2/20 0.34
TUBB4B P68371 2/20 0.34
TUBB3 Q13509 2/20 0.34
TUBB2A Q13885 2/20 0.34
TUBB8 Q3ZCM7 2/20 0.34
TUBA3E Q6PEY2 2/20 0.34
TUBA1A Q71U36 2/20 0.34
TUBA1C Q9BQE3 2/20 0.34
TUBB6 Q9BUF5 2/20 0.34
TUBB2B Q9BVA1 2/20 0.34
TUBB1 Q9H4B7 2/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19932028 0.81 CES1 (0.39) MEN1KMT2ABCL2L1BADMAOB
SCHEMBL19932031 0.77 MEN1 (0.37) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL8960045 0.76 KDM4E (0.49) MEN1KMT2AMAOBLMNAADRA1D
SCHEMBL5770327 0.74 MEN1 (0.40) MEN1KMT2ABCL2L1BADCES1
SCHEMBL19927065 0.74 NOS3 (0.40) MEN1KMT2ABCL2L1BADCES1
SCHEMBL6166597 0.74 CETP (0.38) MEN1KMT2ABCL2L1BADENPP2
SCHEMBL10359950 0.74 MEN1 (0.37) MEN1KMT2ABCL2L1BADMAOB
SCHEMBL17533482 0.73 NOS3 (0.39) MEN1KMT2ABCL2L1BADCES1
SCHEMBL11626560 0.72 ALDH1A1 (0.49) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL31265034 0.72 BCL2L1 (0.39) MEN1KMT2ABCL2L1BADCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349836-B1 TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS LILLY CO ELI (US) 2006-06-14 EP disclosed
US-6992100-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2006-01-31 US disclosed
US-20040092543-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-05-13 US disclosed
EP-1349836-A2 TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2003-10-08 EP disclosed
WO-2002050029-A2 TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092543-A1 Novel spla2 inhibitors PLA2G12A, PLAAT2, SPINT2 MEN1 4836/4885KMT2A 3392/4885BCL2L1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.